Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial
2018 | Zeitschriftenartikel. Eine Publikation mit Affiliation zur Georg-August-Universität Göttingen.
Spring zu: Zitieren & Links | Dokumente & Medien | Details | Versionsgeschichte
Zitiervorschlag
Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial
Ravassa, S.; Trippel, T.; Bach, D.; Bachran, D.; González, A.; López, B. & Wachter, R. u.a. (2018)
European Journal of Heart Failure, 20(9) pp. 1290-1299. DOI: https://doi.org/10.1002/ejhf.1194
Dokumente & Medien
Details
- Titelvariante(n)
- Myocardial fibrosis and effect of spironolactone in HFpEF
- Autor(en)
- Ravassa, Susana; Trippel, Tobias; Bach, Doris; Bachran, Diana; González, Arantxa; López, Begoña; Wachter, Rolf ; Hasenfuss, Gerd ; Delles, Christian; Dominiczak, Anna F.; Pieske, Burkert ; Díez, Javier; Edelmann, Frank
- Erscheinungsdatum
- 2018
- Zeitschrift
- European Journal of Heart Failure
- ISSN
- 1388-9842
- Sprache
- Englisch
